BioCardia (NASDAQ:BCDA – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Earnings & Valuation
This table compares BioCardia and Capricor Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $60,000.00 | 214.48 | -$8.23 million | ($0.64) | -1.33 |
| Capricor Therapeutics | $22.27 million | 23.50 | -$105.04 million | ($2.45) | -3.67 |
BioCardia has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
BioCardia has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Insider and Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for BioCardia and Capricor Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| Capricor Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,841.18%. Capricor Therapeutics has a consensus target price of $30.25, indicating a potential upside of 236.11%. Given BioCardia’s higher possible upside, research analysts plainly believe BioCardia is more favorable than Capricor Therapeutics.
Profitability
This table compares BioCardia and Capricor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -569.36% | -183.15% |
| Capricor Therapeutics | N/A | -56.60% | -43.97% |
Summary
Capricor Therapeutics beats BioCardia on 7 of the 12 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
